Association of baseline characteristics with adverse events (AEs) in the PROpel trial of olaparib (ola) plus abiraterone (abi) as first-line (1L) treatment for metastatic castration-resistant prostate cancer (mCRPC)

---

Armstrong A. J., Saad F., Oya M., Shore N. D., Procopio G., Vianna K., ...Daha Fazla

JOURNAL OF CLINICAL ONCOLOGY, sa.16, 2024 (SCI-Expanded, Scopus)

• Yayın Türü: Makale / Özet
• Basım Tarihi: 2024
• Dergi Adı: JOURNAL OF CLINICAL ONCOLOGY
• Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, PASCAL, CAB Abstracts, CINAHL, Gender Studies Database, International Pharmaceutical Abstracts, Veterinary Science Database
• İstanbul Üniversitesi-Cerrahpaşa Adresli: Hayır